144 related articles for article (PubMed ID: 20956940)
1. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis.
Hill VK; Underhill-Day N; Krex D; Robel K; Sangan CB; Summersgill HR; Morris M; Gentle D; Chalmers AD; Maher ER; Latif F
Oncogene; 2011 Feb; 30(8):978-89. PubMed ID: 20956940
[TBL] [Abstract][Full Text] [Related]
2. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
4. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
[TBL] [Abstract][Full Text] [Related]
5. Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.
Hill VK; Shinawi T; Ricketts CJ; Krex D; Schackert G; Bauer J; Wei W; Cruickshank G; Maher ER; Latif F
BMC Cancer; 2014 Jul; 14():506. PubMed ID: 25012071
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
[TBL] [Abstract][Full Text] [Related]
7. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.
Schagdarsurengin U; Richter AM; Wöhler C; Dammann RH
Epigenetics; 2009 Nov; 4(8):571-6. PubMed ID: 19934646
[TBL] [Abstract][Full Text] [Related]
9. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.
Richter AM; Woods ML; Küster MM; Walesch SK; Braun T; Boettger T; Dammann RH
Oncogene; 2020 Apr; 39(15):3114-3127. PubMed ID: 32047266
[TBL] [Abstract][Full Text] [Related]
10. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.
Tepel M; Roerig P; Wolter M; Gutmann DH; Perry A; Reifenberger G; Riemenschneider MJ
Int J Cancer; 2008 Nov; 123(9):2080-6. PubMed ID: 18709645
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
13. Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.
Alentorn A; Durán-Peña A; Malousi A; Marie Y; Mokhtari K; Sanson M; Hoang-Xuan K; Delattre JY; Idbaih A; Vecht C
J Neurooncol; 2015 Sep; 124(3):385-92. PubMed ID: 26224161
[TBL] [Abstract][Full Text] [Related]
14. RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer.
Li Z; Chang X; Dai D; Deng P; Sun Q
Oncol Rep; 2014 Apr; 31(4):1661-8. PubMed ID: 24573726
[TBL] [Abstract][Full Text] [Related]
15. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
[TBL] [Abstract][Full Text] [Related]
16. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
17. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
[TBL] [Abstract][Full Text] [Related]
18. RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer.
Wei Z; Chen X; Chen J; Wang W; Xu X; Cai Q
Biochem Biophys Res Commun; 2013 Mar; 432(4):632-7. PubMed ID: 23428420
[TBL] [Abstract][Full Text] [Related]
19. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
[TBL] [Abstract][Full Text] [Related]
20. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway.
Li X; Liang Q; Liu W; Zhang N; Xu L; Zhang X; Zhang J; Sung JJ; Yu J
Oncogene; 2016 May; 35(19):2453-64. PubMed ID: 26279301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
